Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq profiling of treatment-sensitive and treatment-resistant breast cancer cell-line samples

ABSTRACT: Bulk RNA sequencing was performed on human breast cancer cell-line samples to compare transcriptomic profiles between treatment-sensitive and treatment-resistant conditions.

ORGANISM(S): Homo sapiens

PROVIDER: GSE337077 | GEO | 2026/07/13

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-seq profiling of FFPE samples from treatment-sensitive and treatment-resistant breast cancer cases

Project description:Bulk RNA sequencing was performed on formalin-fixed paraffin-embedded (FFPE) tumor samples to compare transcriptomic profiles between treatment-sensitive and treatment-resistant breast cancer cases.

2026-07-13 | GSE336901 | GEO

RNA-seq profiling of treatment-sensitive and treatment-resistant breast cancer cell-line samples

Project description:RNA-seq profiling of treatment-sensitive and treatment-resistant breast cancer cell-line samples

| PRJNA1484006 | ENA

RNA-seq profiling of control and treatment breast cancer cell-line samples

Project description:Bulk RNA sequencing was performed on human breast cancer cell-line samples to compare transcriptomic profiles between control and treatment conditions.

2026-07-13 | GSE336903 | GEO

RNA-seq profiling of FFPE samples from treatment-sensitive and treatment-resistant breast cancer cases

Project description:RNA-seq profiling of FFPE samples from treatment-sensitive and treatment-resistant breast cancer cases

| PRJNA1483549 | ENA

RNAseq analysis of treatment-resistant and sensitive breast cancer patient-derived organoids with paclitaxel treatments

Project description:Huntsman Cancer Institute (HCI)-001 patient-derived organoids (PDOs) and HCI-002 PDOs obtained from Huntsman Cancer Institute, University of Utah (Nat Med. 2011 Oct 23;17(11):1514-20). Purpose: The goals of this study is to identify molecular pathways and genes that are involved in the treatment responsiveness of breast cancer PDOs. Methods: mRNA profiles of HCI-001 and HCI-002 PDOs were generated by Illumina NovaSeq 6000 platform for paired-end sequencing, 150-bp read length, for about 20 million raw reads per sample. RNA sequencing FASTQ files were processed with HISAT2 aligner in default mode with the Ensembl human transcriptome annotation (Build version GRCh38 and transcript annotation GRCh38.89). Differential gene expression analysis was performed using DESeq2 software. Enrichment analysis was performed using ClusterProfiler software. Results: We mapped about 20 million sequence reads per sample to the human genome (build HG38) in the RNAs of HCI-001 and HCI-002 PDOs treated with paclitaxel or vehicle. We used a minimum expression cut-off of 1 FPKM in order to exclude low-levels genes and the RNA-seq data confirmed the difference expression of 67 known apoptosis-regulatory genes in treatment-sensitive PDOs (HCI-002) compare to treatment-resistant PDOs (HCI-001). Conclusions: This study identified apoptosis-regulatory genes that are differentially induced or represeed in treatment-sensitive PDOs (HCI-002) or treatment-resistant PDOs (HCI-001).

2021-09-09 | GSE183477 | GEO

Transcription profiling of human breast tumors resistant or sensitive to docetaxel treatment

Project description:This SuperSeries is composed of the following subset Series: GSE349: These patients proved resistant to docetaxel treatment, exhibiting residual tumor of 25% or greater remaining volume. Resistant GSE350 These patients were sensitive to docetaxel treatment, exhibiting less than 25% residual tumor.

2007-10-26 | E-GEOD-6434 | biostudies-arrayexpress

Gene Expression Profile of Resistant vs Sensitive Breast Cancer Tissues to Taxane Treatment

Project description:The present project aims to evaluate the gene expression profile of breast cancer tissue resistant to treatment with taxanes. Biopsies from tumor tissues were obtained from breast cancer patients without prior treatment. Histopathological analysis and ex vivo exposure to antineoplastic chemotherapeutics were carried out. Alamar Blue and lactate dehydrogenase release assays were performed for quantitative analysis of tumor viability after treatment and to asses the sensibility or resistant behaviour. Sensitive and resistant tumor tissues samples without prior exposure to therapeutic drugs were analyzed by gene expression microarrays.

2017-05-24 | GSE99225 | GEO

Nasopharyngeal carcinoma patient samples: radio-sensitive samples vs. radio-resistant samples

Project description:Expression profiling of nasopharyngeal carcinoma patients comparing radio-sensitive samples with radio-resistant samples.

2013-09-21 | GSE32389 | GEO

Nasopharyngeal carcinoma patient samples: radio-sensitive samples vs. radio-resistant samples

Project description:Expression profiling of nasopharyngeal carcinoma patients comparing radio-sensitive samples with radio-resistant samples. Two condition-experiments, radio-sensitive and radio-resistant nasopharyngeal carcinoma patients. Biological replicates: 8 radio-sensitive, 12 radio-resistant, different donors in the same hospital. One patient per array.

2013-09-21 | E-GEOD-32389 | biostudies-arrayexpress

Cetuximab resistant or sensitive head and neck cancer samples

Project description:10 cell lines (five cetuximab sensitive and five cetuximab resistant) were selected for gene copy number array analysis on the Affymetrix SNP 6.0 platform. 39 protein coding genes were amplified in cetuximab resistant cells and normal in sensitive cells, all present on genomic regions 11q22.1 or 5p13-15. Five genes were selected for quantitative PCR verification, namely, YAP1 and TRPC6 (11q22.1) and PDCD6, TPPP, and PTGER4 (5p13-15). An extended panel of totally 10 cetuximab resistant and 10 sensitive cell lines verified that YAP1 amplified cells are cetuximab resistant. YAP1 gene amplification was highly correlated to the YAP1 mRNA expression, which was significantly higher in cetuximab resistant cells than in sensitive. YAP1 downregulation resulted in increased cetuximab sensitivity in one of two cetuximab resistant cell lines investigated and growth inhibition in another. We conclude that YAP1 is a marker for cetuximab resistance in head and neck cancer.

2012-12-01 | GSE36790 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data